MARKET

VRDN

VRDN

Viridian Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.96
+1.57
+10.91%
After Hours: 15.96 0 0.00% 16:34 09/24 EDT
OPEN
14.25
PREV CLOSE
14.39
HIGH
17.14
LOW
14.22
VOLUME
224.12K
TURNOVER
--
52 WEEK HIGH
25.67
52 WEEK LOW
7.08
MARKET CAP
153.01M
P/E (TTM)
-0.5380
1D
5D
1M
3M
1Y
5Y
Viridian Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Preferred Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, today announced the closing of an underwritten public offering of 7,344,543 ...
GlobeNewswire · 1d ago
Top Midday Gainers
MT Newswires · 3d ago
Why Are Viridian Therapeutics Shares Moving Higher On Tuesday?
Benzinga · 3d ago
UUUU, UEC and GOGL among pre market gainers
NanoViricides (NYSE:NNVC) +45%. Viridian Therapeutics (NASDAQ:VRDN) +28% secures $85M capital raise ReWalk Robotics (NASDAQ:RWLK) +22%. BIO-key International (NASDAQ:BKYI) +17%. Sino-Global Shipping America (NASDAQ:SINO) +15% and Hebei Yanghuai Technology ...
Seekingalpha · 3d ago
BRIEF-Viridian Therapeutics Says Announces Pricing Of Public Offering Of Shares Of Common Stock And Preferred Stock
reuters.com · 3d ago
Viridian Therapeutics Prices Offering of Common, Preferred Shares; Expects $85 Million Gross Proceeds
MT Newswires · 3d ago
BRIEF-Viridian Therapeutics Announces Proposed Public Offering Of Common Stock And Preferred Stock
reuters.com · 4d ago
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, today announced that it has commenced an underwritten public offering of sha...
GlobeNewswire · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VRDN. Analyze the recent business situations of Viridian Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VRDN stock price target is 35.20 with a high estimate of 44.00 and a low estimate of 26.00.
EPS
Institutional Holdings
Institutions: 69
Institutional Holdings: 9.20M
% Owned: 95.98%
Shares Outstanding: 9.59M
TypeInstitutionsShares
Increased
10
1.06M
New
4
844.00K
Decreased
4
250.20K
Sold Out
11
1.19M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
President/Chief Executive Officer/Director
Jonathan Violin
Chief Financial Officer
Kristian Humer
Other
Barrett Katz
Director
Jennifer Moses
Independent Director
Peter Harwin
Independent Director
Tomas Kiselak
Independent Director
Arlene Morris
No Data
  • All
  • Financials
  • Insiders
More
About VRDN
Viridian Therapeutics, Inc., formerly Miragen Therapeutics, Inc., is a biotechnology company. The Company is engaged in developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating orphan disease, and has early-stage programs focused on other targets and indications. Its lead candidate, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody (mAb) that is under development for thyroid eye disease (TED). The Company's TED pipeline also includes VRDN-002 and VRDN-003. Its other programs include VRDN-004, which is under development for undisclosed rare orphan disease, and VRDN-005, which is under development for tick-borne disease (TBD). The Company also out licenses its programs.

Webull offers kinds of Viridian Therapeutics Inc stock information, including NASDAQ:VRDN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRDN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VRDN stock methods without spending real money on the virtual paper trading platform.